Sign up to our newsletter Subscribe
The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK

The WHO lists AMR in the top 10 global health threats but new antibiotic development is not keeping pace with the emergence of resistant pathogens. Novel ways to structure the market are being explored which incentivise developers and give healthcare systems new tools to fight AMR.
Notifications